喘息治療市場：製品、薬剤クラス、投与経路別-2025～2030年の世界予測

喘息治療市場は、2023年に247億米ドルと評価され、2024年には272億6,000万米ドルに達すると予測され、CAGR 10.63％で成長し、2030年には501億米ドルに達すると予測されています。

喘息治療市場には、世界中で数百万人が罹患している慢性呼吸器疾患である喘息の症状緩和と管理を目的とした、幅広い製品と治療が含まれています。効果的な喘息治療の必要性は、都市化、汚染、遺伝的感受性などの要因に起因する喘息の有病率の上昇によって強調されています。これらの治療の用途は、気管支拡大薬のような即効性のあるものから、吸入コルチコステロイドや生物製剤のような長期的なコントロール薬まで多岐にわたり、喘息の重症度に応じて調整されます。最終用途の範囲には、主に病院、クリニック、在宅医療の現場が含まれ、患者はそこで治療を受けるか自己管理します。

市場の主要成長要因としては、環境アレルゲンの増加、ドラッグデリバリーシステム（スマート吸入器など）の技術進歩、呼吸器疾患にかかりやすい高齢者の拡大などが挙げられます。新たなビジネス機会は個別化医療にあり、ゲノムや表現型のプロファイリングに焦点を当てた研究が、オーダーメイドの治療戦略につながります。拡大するバイオ医薬品部門も、新規生物製剤の開発を通じて有利な道を示しています。企業はハイテク企業との提携を活用してインテリジェントなモニタリングシステムを開発し、遠隔医療の可能性を活用して患者のアドヒアランスを向上させる必要があります。

しかし、高い治療費、喘息治療の長期使用による副作用の可能性、一貫性のない服薬アドヒアランスといった課題が、市場の成長を妨げています。さらに、規制上の制約や新薬承認のためのパイプラインの遅れが、市場課題に拍車をかけています。事業を確実に成長させるためには、企業は手頃な価格のジェネリック医薬品の開発に注力し、革新的な製剤の研究開発に投資し、喘息管理に対する認識を高めるための教育プログラムを強化すべきです。

喘息治療市場はダイナミックな市場であり、進化する医療ニーズに適応するためには継続的なイノベーションが必要です。高コストに対処し、患者教育を重視することで、企業は患者の転帰に大きな影響を与え、成長機会を生かすことができます。精密医療が先導する中、同市場は大きな進展を遂げようとしています。

市場力学：急速に進化する喘息治療市場の主要市場洞察を公開

喘息治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • 喘息とその他の呼吸器疾患の増加
  • 最近のアレルギー検出・診断技術の向上
  • モノクローナル抗体の需要拡大
• 市場抑制要因
  • 喘息治療デバイスの限界と副作用
• 市場機会
  • 治療のための併用治療の開発
  • 喘息治療のための広範な研究開発（R&D）努力
• 市場課題
  • 遠隔地や農村部における治療法の限定的な普及

ポーターのファイブフォース：喘息治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：喘息治療市場における外部からの影響の把握

外部マクロ環境要因は、喘息治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：喘息治療市場における競合情勢の把握

喘息治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：喘息治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、喘息治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：産業主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 喘息やその他の呼吸器疾患の発生率増加
    • アレルギー検出と診断技術の最近の進歩
    • モノクローナル抗体の需要拡大
  • 抑制要因
    • 喘息治療機器の限界と副作用
  • 機会
    • 治療のための併用療法の開発
    • 喘息治療のための広範な研究開発の取り組み
  • 課題
    • 遠隔地や農村地域では治療の供給が限られている
• 市場セグメンテーション分析
  • 製品：喘息治療用の定量吸入器の需要増加
  • 薬剤クラス：喘息治療における抗炎症薬の使用増加
  • 投与経路：迅速な緩和のための吸入喘息薬の採用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境
• 顧客のカスタマイズ

第6章 喘息治療市場：製品別

• イントロダクション
• 吸入器
  • ドライ粉末吸入器
  • 定量吸入器
  • ソフトミスト吸入器
• ネブライザー

第7章 喘息治療市場：薬剤クラス別

• イントロダクション
• 抗炎症
• 気管支拡大薬
• 併用療法

第8章 喘息治療市場：投与経路別

• イントロダクション
• 吸入
• 経口

第9章 南北アメリカの喘息治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の喘息治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの喘息治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • GSK、14億米ドルのAiolos Bio買収で呼吸器ポートフォリオを強化
  • TevaとBiolojic Design、アトピー性皮膚炎と喘息の治療用抗体の開発に関する独占ライセンス契約を発表
  • Lupin、成人喘息とCOPD治療「ルフォーベック（R）100/6」を発売

企業一覧

• Genentech, Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd.
• Chiesi Farmaceutici S.p.A.
• Boston Scientific Corporation
• Sunovion Pharmaceuticals, Inc.
• Medtronic PLC
• Softhale NV by invoX Pharma Limited
• Koninklijke Philips N.V.
• Wellinks, Inc.
• Viatris Inc.
• Amgen Inc.
• Sanofi S.A.
• Biogen Inc.
• AstraZeneca PLC
• Merck & Co, Inc.
• Parekhplast India Limited
• GlaxoSmithKline PLC
• Kare Medical and Analytical Devices Ltd. Co.
• Sun Pharmaceutical Industries Limited
• Abbott Laboratories
• Shenzhen Aeon Technology Co., Ltd.
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd
• Lupin Limited
• Trudell Medical Limited
• Cipla Limited
• Merxin Ltd.
• Novartis AG
• Regeneron Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. ASTHMA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ASTHMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ASTHMA THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Asthma Therapeutics Market was valued at USD 24.70 billion in 2023, expected to reach USD 27.26 billion in 2024, and is projected to grow at a CAGR of 10.63%, to USD 50.10 billion by 2030.

The asthma therapeutics market encompasses a wide array of products and treatments aimed at alleviating symptoms and managing asthma, a chronic respiratory condition affecting millions globally. The necessity for effective asthma therapeutics is underscored by the rising prevalence of asthma, attributable to factors such as urbanization, pollution, and genetic susceptibility. The application of these therapeutics spans from quick-relief medications, like bronchodilators, to long-term control agents, including inhaled corticosteroids and biologics, tailored to various grades of asthma severity. End-use scope primarily includes hospitals, clinics, and homecare settings, where patients either receive or self-administer treatment.

Key growth influencers in the market include an increase in environmental allergens, technological advancements in drug delivery systems (like smart inhalers), and an expanding geriatric population who are more prone to respiratory ailments. Emerging opportunities lie in personalized medicine, with research focusing on genomic and phenotypic profiling leading to tailored therapeutic strategies. The expanding biopharmaceutical sector also presents lucrative avenues through the development of novel biologics. Companies should leverage partnerships with tech firms to develop intelligent monitoring systems and improve patient adherence, tapping into the potential of telemedicine.

However, market growth is hindered by challenges such as high treatment costs, potential side effects of long-term asthma medication use, and inconsistent medical adherence. Furthermore, regulatory constraints and a slow pipeline for new drug approvals add to market challenges. To ensure business growth, companies should focus on developing affordable generics, invest in R&D for innovative drug formulations, and enhance educational programs to raise awareness of asthma management.

The asthma therapeutics market is dynamic, requiring continuous innovation to adapt to evolving healthcare needs. By addressing high costs and emphasizing patient education, businesses can significantly impact patient outcomes and capitalise on growth opportunities. With precision medicine leading the way, the market is poised for significant advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Asthma Therapeutics Market

The Asthma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing Incidences of Asthma and Other Respiratory Diseases
  • Recent Improvements in Allergy Detection and Diagnostic Technologies
  • Extensive Demand for Monoclonal Antibodies
• Market Restraints
  • Limitation and Side Effects of Asthma Therapeutic Devices
• Market Opportunities
  • Development of Combination Therapeutics for The Treatment
  • Extensive Research and Development (R&D) Efforts for Asthma Treatment
• Market Challenges
  • Limited Therapeutics Reach in Remote & Rural Areas

Porter's Five Forces: A Strategic Tool for Navigating the Asthma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Asthma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Asthma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Asthma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Asthma Therapeutics Market

A detailed market share analysis in the Asthma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Asthma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Asthma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Genentech, Inc., Pfizer Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Boston Scientific Corporation, Sunovion Pharmaceuticals, Inc., Medtronic PLC, Softhale NV by invoX Pharma Limited, Koninklijke Philips N.V., Wellinks, Inc., Viatris Inc., Amgen Inc., Sanofi S.A., Biogen Inc., AstraZeneca PLC, Merck & Co, Inc., Parekhplast India Limited, GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Sun Pharmaceutical Industries Limited, Abbott Laboratories, Shenzhen Aeon Technology Co., Ltd., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Lupin Limited, Trudell Medical Limited, Cipla Limited, Merxin Ltd., Novartis AG, and Regeneron Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Inhalers and Nebulizers. The Inhalers is further studied across Dry Powder Inhalers, Metered-Dose Inhalers, and Soft Mist Inhalers.
• Based on Drug Class, market is studied across Anti-Inflammatory, Bronchodilators, and Combination Therapy.
• Based on Route of administration, market is studied across Inhaled and Oral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing Incidences of Asthma and Other Respiratory Diseases
    • 5.1.1.2. Recent Improvements in Allergy Detection and Diagnostic Technologies
    • 5.1.1.3. Extensive Demand for Monoclonal Antibodies
  • 5.1.2. Restraints
    • 5.1.2.1. Limitation and Side Effects of Asthma Therapeutic Devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of Combination Therapeutics for The Treatment
    • 5.1.3.2. Extensive Research and Development (R&D) Efforts for Asthma Treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Therapeutics Reach in Remote & Rural Areas
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for metered dose inhalers for the treatment of asthma
  • 5.2.2. Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
  • 5.2.3. Route of administration: Expanding adoption of inhaled asthma medication for fast relief
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Asthma Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Inhalers
  • 6.2.1. Dry Powder Inhalers
  • 6.2.2. Metered-Dose Inhalers
  • 6.2.3. Soft Mist Inhalers
• 6.3. Nebulizers

7. Asthma Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Anti-Inflammatory
• 7.3. Bronchodilators
• 7.4. Combination Therapy

8. Asthma Therapeutics Market, by Route of administration

• 8.1. Introduction
• 8.2. Inhaled
• 8.3. Oral

9. Americas Asthma Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Asthma Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Asthma Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
  • 12.3.2. Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
  • 12.3.3. Lupin Launches Luforbec(R) 100/6 for Adult Asthma and COPD Treatment

Companies Mentioned

• 1. Genentech, Inc.
• 2. Pfizer Inc.
• 3. Takeda Pharmaceutical Company
• 4. Teva Pharmaceutical Industries Ltd.
• 5. Chiesi Farmaceutici S.p.A.
• 6. Boston Scientific Corporation
• 7. Sunovion Pharmaceuticals, Inc.
• 8. Medtronic PLC
• 9. Softhale NV by invoX Pharma Limited
• 10. Koninklijke Philips N.V.
• 11. Wellinks, Inc.
• 12. Viatris Inc.
• 13. Amgen Inc.
• 14. Sanofi S.A.
• 15. Biogen Inc.
• 16. AstraZeneca PLC
• 17. Merck & Co, Inc.
• 18. Parekhplast India Limited
• 19. GlaxoSmithKline PLC
• 20. Kare Medical and Analytical Devices Ltd. Co.
• 21. Sun Pharmaceutical Industries Limited
• 22. Abbott Laboratories
• 23. Shenzhen Aeon Technology Co., Ltd.
• 24. Boehringer Ingelheim GmbH
• 25. F. Hoffmann-La Roche Ltd
• 26. Lupin Limited
• 27. Trudell Medical Limited
• 28. Cipla Limited
• 29. Merxin Ltd.
• 30. Novartis AG
• 31. Regeneron Pharmaceuticals, Inc.